Emerging News and Research in Prostate Cancer Imaging — July 2024

Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.

Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Microultrasonography-guided biopsy offered comparable detection as MRI/conventional ultrasound-guided biopsy in detection of Gleason grade group 2 or higher prostate cancer, according to a new international multicenter study.

Indicated for use in cases involving suspected metastasis with PCa or suspected PCa recurrence due to elevated PSA level, Gozellix reportedly has a longer shelf life than other gallium-based PET imaging products.

While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.

Researchers noted the combination of AI and bpMRI had an average AUC of 91 percent for csPCa detection in contrast to 78 percent for unassisted radiologist interpretation in a recent meta-analysis.